This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Mestastop Solutions PVT Ltd - ONSITE PRESENTER


Currently, there are almost no drugs to delay or prevent the process of cancer metastasis. Mestastop has created three proprietary platforms, both in vitro and in vivo, along with patient tumour translational validation, to unravel the complexity of metastasis drug discovery and early predictive diagnostics. These platforms are ready to be partnered for oncology drug discovery, drug repurposing and profiling current anti-cancer leads or candidates for their anti-metastatic effect. Mestastop has also identified one first-in-class target for metastasis, with genetic overexpression and CRISPR CAS knockdown data.

Mestastop is based out of Marlton, New Jersey and Bangalore, Karnataka. Mestastop has a senior advisory team of Dr John Ellingboe (ex-Wyeth) and Dr Ajith Kamath (ex-Pfizer) with a cumulative experience of 60 years. A medical advisory team of medical oncologists with a cumulative experience greater than 120 years oversees the patient clinical studies. 

Identified by the UK-based Global Health and Pharma as the best "Metastasis R&D specialists, 2022", Mestastop is further supported by Machine Learning and Animal Pharmacology consultants.

With two international patent applications, Mestastop has raised funds from Angels and VCs with non-dilutive Grants from the Federal Government.

We're bringing you

  • Company Presentations